Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26901678 | 0.84 | PDPK1 (0.39) | HTR2AHRH1AOC3TDP1RAB9A | |
| SCHEMBL25259601 | 0.81 | AOC3 (0.44) | CYP1A2CYP2D6CYP2C9CYP2C19NPSR1 | |
| SCHEMBL31068689 | 0.81 | AOC3 (0.44) | CYP1A2CYP2D6CYP2C9CYP2C19NPSR1 | |
| SCHEMBL25299772 | 0.81 | PARP1 (0.36) | PARP1CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL31068718 | 0.81 | PARP1 (0.36) | PARP1CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL25852502 | 0.81 | TSHR (0.36) | HTR2AHRH1AOC3TDP1 | |
| SCHEMBL25852412 | 0.81 | S1PR1 (0.47) | HTR2AHRH1AOC3TDP1 | |
| SCHEMBL21205740 | 0.80 | PARP1 (0.45) | PARP1CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL25833224 | 0.79 | AOC3 (0.33) | HTR2AHRH1AOC3TDP1RAB9A | |
| SCHEMBL11509121 | 0.77 | PARP1 (0.43) | PARP1CYP1A2CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827637-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2023-11-28 | — | — | US | disclosed |
| US-20230227451-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827637-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | MAPKAPK2, MAPK1, MAPK7 | PARP1 1494/4885CYP1A2 495/4885CYP2D6 552/4885 |
| US-20230227451-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPK7 | PARP1 1494/4885CYP1A2 495/4885CYP2D6 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.